WallStreetZenWallStreetZen

NASDAQ: COGT
Cogent Biosciences Inc Stock

$7.23+0.23 (+3.29%)
Updated Mar 1, 2024
COGT Price
$7.23
Fair Value Price
$0.43
Market Cap
$751.29M
52 Week Low
$3.67
52 Week High
$13.51
P/E
-2.99x
P/B
2.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$192.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$154M
Beta
0.97
Next Earnings
Mar 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

COGT Overview

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how COGT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

COGT ($7.23) is overvalued by 1,575.38% relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COGT ($7.23) is not significantly undervalued (1,575.38%) relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COGT due diligence checks available for Premium users.

Be the first to know about important COGT news, forecast changes, insider trades & much more!

COGT News

Valuation

COGT fair value

Fair Value of COGT stock based on Discounted Cash Flow (DCF)
Price
$7.23
Fair Value
$0.43
Overvalued by
1,575.38%
COGT ($7.23) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COGT ($7.23) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

COGT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.99x
Industry
15.19x
Market
36.17x

COGT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.91x
Industry
6.18x
COGT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

COGT's financial health

Profit margin

Revenue
$0.0
Net Income
-$54.4M
Profit Margin
0%
COGT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$313.4M
Liabilities
$55.6M
Debt to equity
0.22
COGT's short-term assets ($270.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COGT's short-term assets ($270.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COGT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COGT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$44.1M
Investing
$10.5M
Financing
$0.0
COGT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

COGT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
COGT$751.29M+3.29%-2.99x2.91x
PHAR$749.42M-0.71%-32.76x3.39x
ALXO$748.78M+2.45%-4.21x4.44x
CCCC$753.92M+0.09%-4.12x3.06x
NVAX$754.35M+9.11%-1.00x-1.05x

Cogent Biosciences Stock FAQ

What is Cogent Biosciences's quote symbol?

(NASDAQ: COGT) Cogent Biosciences trades on the NASDAQ under the ticker symbol COGT. Cogent Biosciences stock quotes can also be displayed as NASDAQ: COGT.

If you're new to stock investing, here's how to buy Cogent Biosciences stock.

What is the 52 week high and low for Cogent Biosciences (NASDAQ: COGT)?

(NASDAQ: COGT) Cogent Biosciences's 52-week high was $13.51, and its 52-week low was $3.67. It is currently -46.48% from its 52-week high and 97% from its 52-week low.

How much is Cogent Biosciences stock worth today?

(NASDAQ: COGT) Cogent Biosciences currently has 103,913,396 outstanding shares. With Cogent Biosciences stock trading at $7.23 per share, the total value of Cogent Biosciences stock (market capitalization) is $751.29M.

Cogent Biosciences stock was originally listed at a price of $44.44 in Mar 29, 2018. If you had invested in Cogent Biosciences stock at $44.44, your return over the last 5 years would have been -83.73%, for an annualized return of -30.45% (not including any dividends or dividend reinvestments).

How much is Cogent Biosciences's stock price per share?

(NASDAQ: COGT) Cogent Biosciences stock price per share is $7.23 today (as of Mar 1, 2024).

What is Cogent Biosciences's Market Cap?

(NASDAQ: COGT) Cogent Biosciences's market cap is $751.29M, as of Mar 5, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cogent Biosciences's market cap is calculated by multiplying COGT's current stock price of $7.23 by COGT's total outstanding shares of 103,913,396.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.